Trial Profile
A Phase 2 Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2023
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Nazartinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 26 May 2023 Planned End Date changed from 31 Oct 2025 to 30 Jun 2024.
- 26 May 2023 Planned primary completion date changed from 31 Oct 2022 to 31 Dec 2023.
- 21 Jan 2022 Status changed from recruiting to active, no longer recruiting.